Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.

Connection

Ruofei Du to Male

This is a "connection" page, showing publications Ruofei Du has written about Male.

 
Connection Strength
 
 
 
0.108
 
  1. Du R, Wang X, Ma L, Larcher LM, Tang H, Zhou H, Chen C, Wang T. Adverse reactions of targeted therapy in cancer patients: a retrospective study of hospital medical data in China. BMC Cancer. 2021 Feb 28; 21(1):206.
    View in: PubMed
    Score: 0.043
  2. Wang R, Tang H, Cui P, Du R, Wang P, Sun Q, Fu H, Lu H, Li X, Zhang T, Chen C. The influence of resourcefulness on the family functioning of young- and middle-aged lymphoma patients in China: a cross-sectional study. Fam Pract. 2024 Jun 12; 41(3):360-368.
    View in: PubMed
    Score: 0.014
  3. Lauer RC, Barry M, Smith TL, Thomas AM, Wu J, Du R, Lee JH, Rao A, Dobroff AS, Arap MA, Nunes DN, Silva IT, Dias-Neto E, Chen I, McCance DJ, Cavenee WK, Pasqualini R, Arap W. Dysregulation of the PRUNE2/PCA3 genetic axis in human prostate cancer: from experimental discovery to validation in two independent patient cohorts. Elife. 2023 01 16; 12.
    View in: PubMed
    Score: 0.012
  4. Zhang ZB, Xiong LL, Xue LL, Deng YP, Du RL, Hu Q, Xu Y, Yang SJ, Wang TH. MiR-127-3p targeting CISD1 regulates autophagy in hypoxic-ischemic cortex. Cell Death Dis. 2021 03 15; 12(3):279.
    View in: PubMed
    Score: 0.011
  5. Xue LL, Wang F, Xiong LL, Du RL, Zhou HL, Zou Y, Wu MX, Yang MA, Dai J, He MX, Wang TH. A single-nucleotide polymorphism induced alternative splicing in Tacr3 involves in hypoxic-ischemic brain damage. Brain Res Bull. 2020 01; 154:106-115.
    View in: PubMed
    Score: 0.010
  6. Nozadi SS, Li L, Clifford J, Du R, Murphy K, Chen L, Seanez P, Burnette C, MacKenzie D, Lewis JL. Use of Ages and Stages Questionnaires? (ASQ) in a Navajo population: Comparison with the U.S. normative dataset. Child Care Health Dev. 2019 09; 45(5):709-718.
    View in: PubMed
    Score: 0.010
  7. Patt YZ, Murad W, Fekrazad MH, Baron AD, Bansal P, Boumber Y, Steinberg K, Lee SJ, Bedrick E, Du R, Lee FC. INST OX-05-024: first line gemcitabine, oxaliplatin, and erlotinib for primary hepatocellular carcinoma and bile duct cancers: a multicenter Phase II trial. Cancer Med. 2017 Sep; 6(9):2042-2051.
    View in: PubMed
    Score: 0.008
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.